期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
High Level Radioactive Waste Disposal in China
1
作者 Ju Wang Beijing Research Institute of Uranium Geology,Beijing 100029,China. 《地学前缘》 EI CAS CSCD 北大核心 2009年第S1期190-190,共1页
The Chinese government has decided that the installed capacity of nuclear power plants(NPP)will reach 40 GW by the year of 2020,while other 18 GW under construction,and the electricity produced by NPPs will make up 4%... The Chinese government has decided that the installed capacity of nuclear power plants(NPP)will reach 40 GW by the year of 2020,while other 18 GW under construction,and the electricity produced by NPPs will make up 4%of the whole installed capacity. In such case,the spent fuel generated from those NPPs will reach 82630 tons by 2050.The Chinese policy is that,the spent fuel from light water reactors will be reprocessed first,followed by verification and 展开更多
关键词 HLW dISPOSAL r&d program SITE SELECTION BENTONITE
在线阅读 下载PDF
美国航空研发管理机制及对我国的启示--以“持续降低能耗、排放和噪声”研发专项为例
2
作者 张爱霞 郑彦宁 《科技管理研究》 2025年第11期33-40,共8页
基于美国国家航空研发政策,梳理了其国家主导全面布局、联邦机构分工合作、层层规划落实、联合各种力量协同推进的研发战略规划特点。以此为背景,对联邦航空管理局持续降低能耗、排放和噪声(CLEEN)研发专项进行总结,指出其具有阶段目标... 基于美国国家航空研发政策,梳理了其国家主导全面布局、联邦机构分工合作、层层规划落实、联合各种力量协同推进的研发战略规划特点。以此为背景,对联邦航空管理局持续降低能耗、排放和噪声(CLEEN)研发专项进行总结,指出其具有阶段目标指标清晰超前、加速技术成熟应用、公私合作、成本分摊、共担风险等特征,并对其全周期技术转化管理、工作组和遴选主管相结合的遴选方式、专业人员全程深度监管以及同步报告、评估与监督等过程管理方式进行分析。借鉴以上经验,我国在进行关键领域先进技术研发布局和组织实施时,可从创新全链条进行全领域布局,强化重点领域关键环节重大技术的协同开发,加大对共性关键技术成熟转化的投资引导力度,完善全流程监管、报告和信息公开机制。 展开更多
关键词 航空研发 技术研发 研发管理 公私合作 cleen研发专项
在线阅读 下载PDF
Company Profile
3
《China's Refractories》 CAS 2012年第3期41-41,共1页
Liaoning Dalmond Group (shorten for Dalmond), established in 2001, is located on Yingkou City with abundant magnesia resource. Through several years struggle, Dalmond develops to an enterprise group holding several ... Liaoning Dalmond Group (shorten for Dalmond), established in 2001, is located on Yingkou City with abundant magnesia resource. Through several years struggle, Dalmond develops to an enterprise group holding several company branches. 展开更多
关键词 OFFICE A Proiect of National Key technology r&d program Undertaken by LIrr Passed Achievement Appraisal of Henan Province
在线阅读 下载PDF
Evolution of drug regulations and regulatory innovation for anticancer drugs in China 被引量:4
4
作者 Yang Liu Ning Zhang +12 位作者 Cuicui Xie Yale Jiang Yunhe Qin Liyun Zhou Yi Fan Lianjie Ren Chen Yin Huan Yang Wei Xie Qing Zhai Guanqiao Li Hongzhuan Chen Xiaoyuan Chen 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2022年第12期4365-4377,共13页
Over the past two decades,China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals,keeping in line with the rapidly growing scientific innovat... Over the past two decades,China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals,keeping in line with the rapidly growing scientific innovation in drug research and development(R&D).In this study,we outlined the revolution of drug regulation in China since the establishment of the State Drug Administration in 1998.More particularly,we performed a comprehensive analysis of newly approved anticancer drugs in China from the year 2005 to May 2021,as a powerful illustration of how the revolution has changed the drug R&D landscape.Innovative drug development in China has boomed,benefiting in particular from pro-innovation policies as well as expedited program designations by the authority.We found a significant increase in the number of both imported and domestic new anticancer drugs from 2005 to 2021,with the emergence of drugs with novel mechanisms of action,including immune checkpoint inhibitors and cell therapy products.Drug lag has also been dramatically shortened by more than 70%for imported drugs in years 2016-2020 compared to years 2006-2010.Furthermore,we provide an insight into the potential approaches to further optimize the science-based and clinical value-based regulatory and R&D drug ecosystem in China.This review provides evidence of significant impacts of regulations and policies on drug R&D and suggests that the constantly adapting regulatory ecosystem will speed up drug development in China and worldwide. 展开更多
关键词 regulatory innovations drug r&d Anticancer drugs Innovative drugs Expedited program designations drug lag GLOBALIZATION Unmet medical need
原文传递
Advances in artificial design of light-driven carbon dioxide reductase
5
《Science Foundation in China》 CAS 2018年第4期32-32,共1页
With the support by the National Key R&D Program of China,the National Natural Science Foundation of China,and the Chinese Academy of Sciences,the research team led by Prof.Wang JiangYun (王江云) at the Institute ... With the support by the National Key R&D Program of China,the National Natural Science Foundation of China,and the Chinese Academy of Sciences,the research team led by Prof.Wang JiangYun (王江云) at the Institute of Biophysics,CAS,rationally designed a genetically encoded photosensitizer protein (PSP)that facilitates photocatalytic CO2 reduction,which was published in Nature Chemistry (2018, DOI :10.1038/s41557-018-0150-4). 展开更多
关键词 the National KEY r&d program WANG JiangYun
原文传递
常见基金项目的英文名称
6
作者 本刊编辑部 《中华放射医学与防护杂志》 北大核心 2025年第5期415-415,共1页
国家自然科学基金:National Natural Science Foundation of China(NSFC)国家高技术研究发展计划(863计划):National High-tech R&D Program of China(863 Program)国家重点基础研究发展计划项目(973计划):National Program on Key ... 国家自然科学基金:National Natural Science Foundation of China(NSFC)国家高技术研究发展计划(863计划):National High-tech R&D Program of China(863 Program)国家重点基础研究发展计划项目(973计划):National Program on Key Basic Research Project of China(973 Program)。 展开更多
关键词 program national natural science foundation china National High-tech r&d program of China key basic research project national program key basic research project china
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部